trans-1-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine hydrochloride | 103150-29-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: trans-1-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine hydrochloride
• 英文别名: dl-centchroman；hydron;1-[2-[4-[(3R,4R)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrochromen-4-yl]phenoxy]ethyl]pyrrolidine;chloride
• CAS: 103150-29-4
• 化学式: C₃₀H₃₅NO₃*ClH
• 分子量: 494.074
• InChiKey: ZRGUGBSQWQXLHB-XZVFQGBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.68
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  trans-1-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine hydrochloride 生成 l-3,4-trans-2,2-dimethyl-3-phenyl-4--7-methoxychroman
  参考文献：
  名称：

  Studies in antifertility agents. 50. Stereoselective binding of d- and l-centchromans to estrogen receptors and their antifertility activity

  摘要：

  Centchroman [dl-3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl] - 7-methoxychroman hydrochloride], an antifertility agent under clinical evaluation, has been resolved into its optical enantiomers. The cytosol estrogen receptor binding affinity and estrogenic, antiestrogenic and antiimplantation activities of the two enantiomers have been determined. The enantiomers display a 7-fold difference in receptor affinity, and a corresponding difference in stimulation of the uterine growth and antiimplantation activity was observed in rats.

  DOI：

  10.1021/jm00159a044
• 作为产物：
  描述：

  4-(4-hydroxyphenyl)-7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydrobenzopyran 、 N-(2-氯乙基)吡咯烷 生成 trans-1-[2-[4-(7-methoxy-2,2-dimethyl-3-phenyl-3,4-dihydro-2H-1-benzopyran-4-yl)phenoxy]ethyl]pyrrolidine hydrochloride
  参考文献：
  名称：

  SALMAN, M.;ARORA, P. K.;RAY, SUPRABHAT;SRIMAL, R. C., INDIAN J. PHARM. SCI., 49,(1987) N 2, 43-47

  摘要：

  DOI：

文献信息

• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF TRANS 3,4- DIARYLCHROMAN AND THEIR DERIVATIVES<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION DE 3,4- DIARYLCHROMANE ET LEURS DÉRIVÉS
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2009078029A2

  公开（公告）日：2009-06-25

  The invention describes an improved and advantageous process of preparation of trans 3,4-diarylchroman and similar derivatives there of, useful as anti-fertility, anti-osteoporotic and breast cancer drugs. Condensation of arenes with 2,2- dialkyl-3-aryl chromene in presence of a Lewis acid furnishes trans -3,4-diaryl- 2,2-dialkylchroman exclusively. Thus trans-2,2-dimethyl-3-phenyl-4-(4- hydroxyphenyl) chroman the precursor of Ormeloxifene is obtained in excellent yield by hydroarylation of phenol with 2,2-dimethyl-3-phenyl chromene.

  该发明描述了一种改进和优越的制备过程，用于制备反避孕、抗骨质疏松和乳腺癌药物的类似物，其中包括转型3,4-二芳基色基烷和其衍生物。在Lewis酸存在下，芳烃与2,2-二烷基-3-芳基色基烷缩合，仅生成反式-3,4-二芳基-2,2-二烷基色基烷。因此，通过苯酚与2,2-二甲基-3-苯基色基烷的氢化芳基化反应，优良的收率得到了Ormeloxifene的前体反式-2,2-二甲基-3-苯基-4-(4-羟基苯基)色基烷。
• Controlled release modifying complex and pharmaceutical compositions thereof
  申请人：Glenmark Pharmaceuticals Ltd.

  公开号：US20040185097A1

  公开（公告）日：2004-09-23

  Disclosed is a controlled release modifying complex for solid oral controlled release pharmaceutical compositions suitable for once-a-day administration. The composition comprises an active pharmaceutical ingredient, a release modifying complex and other required pharmaceutically acceptable excipients. The release modifying complex comprises a primary release modifying agent, a secondary release modifying agent and an auxiliary release modifying agent or varying combinations thereof, wherein said primary, secondary and auxiliary release modifying agents are present in amounts that synergistically effect and extend the release of active pharmaceutical ingredient.

  本发明公开了一种用于固体口服控释药物组合物的控释调节复合物，该组合物适用于一天一次给药。该组合物包括一种活性药物成分、一种释放调节复合物和其他所需的药学上可接受的辅料。释放调节复合物包括主释放调节剂、次释放调节剂和辅助释放调节剂或它们的不同组合，其中所述主释放调节剂、次释放调节剂和辅助释放调节剂的含量可协同作用并延长活性药物成分的释放。
• CRYSTALLINE (-)-3R,4R-TRANS-7-METHOXY-2,2-DIMETHYL-3-PHENYL-4-[4- 2-(PYRROLIDIN-1-YL)ETHOXY]PHENYL CHROMANE, HYDROGEN FUMARATE
  申请人：NOVO NORDISK A/S

  公开号：EP0912543B1

  公开（公告）日：2004-03-24
• CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF
  申请人：Glenmark Pharmaceuticals Limited

  公开号：EP1599190A2

  公开（公告）日：2005-11-30
• SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR TREATMENT OF PANCREATIC CANCER
  申请人：CIPLA LIMITED

  公开号：US20210299098A1

  公开（公告）日：2021-09-30

  Disclosed is a method for treating of cancer, specifically pancreatic cancer by administering a selective estrogen receptor modulator (SERM), e.g., levormeloxifene, alone or in combination with one or more additional cancer therapies.